On the other hand, as discussed at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019, we understand that the novel treatment of 177Lu-PSMA-617 radioligand therapy for metastatic prostate cancer is one of the most attractive candidates (56, 57). This evidence concerns the gene FOLH1 and metastatic prostate carcinoma.